Prospective Evaluation of Proteinuria and Renal Function in Diabetic Patients With Progressive Renal Disease (PLANET 1)

• ClinicalTrials.gov Identifier: NCT00296374
• Recruitment Status: Completed
• First Posted: February 27, 2006
• Results First Posted: December 30, 2010
• Last Update Posted: September 1, 2011
• Sponsor: AstraZeneca
• Information provided by (Responsible Party): AstraZeneca

Study Description

Brief Summary:

The purpose of this study is to evaluate the effects of Crestor (rosuvastatin) and (Lipitor) atorvastatin on urinary protein excretion over 1 year in patients with Type 1 or 2 diabetes with moderate proteinuria and hypercholesterolaemia.

Condition or disease	Intervention/treatment	Phase
Diabetes Mellitus	Drug: Rosuvastatin; Drug: Atorvastatin	Phase 2

Study Design

• Study Type: Interventional (Clinical Trial)
• Actual Enrollment: 353 participants
• Allocation: Randomized
• Intervention Model: Parallel Assignment
• Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
• Primary Purpose: Treatment
• Official Title: Randomised, Double-blind, 52-wk, Parallel-grp, Multicentre, PIIb Study to Evaluate Effects of Rosuvastatin 10mg, Rosuvastatin 40mg and Atorvastatin 80mg on Urinary Protein Excretion in Hypercholesterolaemic Diabetic Patients With Moderate Proteinuria
• Study Start Date: February 2006
• Actual Primary Completion Date: March 2009
• Actual Study Completion Date: March 2009

Arms and Interventions

Arm	Intervention/treatment
Experimental: 1; Rosuvastatin 10 mg	Drug: Rosuvastatin; 10 mg oral dose administered once daily for 52 weeks; Other Name: Crestor
Experimental: 2; Rosuvastatin 40 mg	Drug: Rosuvastatin; 20 mg oral dose administered once daily for 4 weeks followed by 40 mg oral dose administered once daily for 48 weeks; Other Name: Crestor
Active Comparator: 3; Atorvastatin 80 mg	Drug: Atorvastatin; 40 mg oral dose administered once daily for 4 weeks followed by 80 mg oral dose administered once daily for 48 weeks; Other Name: Lipitor

Outcome Measures

Primary Outcome Measures :

1. Urinary Protein/Creatinine Ratio in Patients With Type 1 or 2 Diabetes. [ Time Frame: Assessed at Week 52, Last observation carried forward (LOCF) ]
   Urinary protein/creatinine ratio (mg/g) =urine protein concentration (mg/dL)/ urine creatinine concentration (g/dL). Outcome measure is the ratio of Week 52 [LOCF] urine protein/creatinine ratio over baseline urine protein/creatinine ratio.

Secondary Outcome Measures :

1. Urinary Protein/Creatinine Ratio at Week 26. [ Time Frame: Assessed at Week 26 ]
   Urinary protein/creatinine ratio (mg/g) =urine protein concentration (mg/dL)/ urine creatinine concentration (g/dL). Outcome measure is the ratio of Week 26 urine protein/creatinine ratio over baseline urine protein/creatinine ratio.
2. Urinary Albumin/Creatinine Ratio at Week 26 [ Time Frame: Assessed at Week 26 ]
   Urinary albumin/creatinine ratio (mg/g) =urine albumin concentration (mg/dL)/ urine creatinine concentration (g/dL). Outcome measure is the ratio of Week 26 urine albumin/creatinine ratio over baseline urine albumin/creatinine ratio.
3. Urinary Albumin/Creatinine Ratio at Week 52 [LOCF] [ Time Frame: Assessed at Week 52 LOCF ]
   Urinary albumin/creatinine ratio (mg/g) =urine albumin concentration (mg/dL)/ urine creatinine concentration (g/dL). Outcome measure is the ratio of Week 52 [LOCF] urine albumin/creatinine ratio over baseline urine albumin/creatinine ratio.
4. Change From Baseline in Estimated Glomerular Filtration Rate (eGFR) at Week 26 [ Time Frame: Assessed at Baseline and Week 26 ]
5. Change From Baseline in eGFR at Week 52 [LOCF] [ Time Frame: Assessed at Baseline and Week 52 [LOCF] ]
6. Correlation Coefficient Urinary Protein/Creatinine Ratio and Total Cholesterol [TC] Indicating the Relationship Between Renal Effects and Lipid Changes [ Time Frame: 52 weeks ]
   Correlation of changes from baseline in urinary protein/creatinine ratio with percent change from baseline in lipids and lipoprotein concentrations at Week 52 (LOCF).
7. Relationship Between Renal Effects and Lipid Changes: Urinary Protein/Creatinine Ratio TC [ Time Frame: Assessed at 52 Weeks ]
   Correlation of changes from baseline in urinary protein/creatinine ratio with percent change from baseline in lipids and lipoprotein concentrations at Week 52
8. Relationship Between Renal Effects and Lipid Changes: Urinary Protein/Creatinine Ratio and Low Density Lipoprotein Cholesterol [LDL-C] [ Time Frame: 26 weeks ]
   Correlation of changes from baseline in urinary protein/creatinine ratio with percent change from baseline in lipids and lipoprotein concentrations at Week 26.
9. Relationship Between Renal Effects and Lipid Changes: Urinary Protein/Creatinine Ratio and LDL-C [ Time Frame: 52 Weeks ]
   Correlation of changes from baseline in urinary protein/creatinine ratio with percent change from baseline in lipids and lipoprotein concentrations at Week 52
10. Relationship Between Renal Effects and Lipid Changes: Urinary Protein/Creatinine Ratio and High Density Lipoprotein Cholesterol [HDL-C] [ Time Frame: 26 weeks ]
    Correlation of changes from baseline in urinary protein/creatinine ratio with percent change from baseline in lipids and lipoprotein concentrations at Week 26.
11. Relationship Between Renal Effects and Lipid Changes: Urinary Protein/Creatinine Ratio and HDL-C [ Time Frame: 52 Weeks ]
    Correlation of changes from baseline in urinary protein/creatinine ratio with percent change from baseline in lipids and lipoprotein concentrations at Week 52
12. Relationship Between Renal Effects and Lipid Changes: Urinary Protein/Creatinine Ratio and Non-high Density Lipoprotein Cholesterol [nonHDL-C] [ Time Frame: 26 weeks ]
    Correlation of changes from baseline in urinary protein/creatinine ratio with percent change from baseline in lipids and lipoprotein concentrations at Week 26.
13. Relationship Between Renal Effects and Lipid Changes: Urinary Protein/Creatinine Ratio and nonHDL-C [ Time Frame: 52 Weeks ]
    Correlation of changes from baseline in urinary protein/creatinine ratio with percent change from baseline in lipids and lipoprotein concentrations at Week 52
14. Relationship Between Renal Effects and Lipid Changes: Urinary Protein/Creatinine Ratio and Triglyceride [TG] [ Time Frame: 26 weeks ]
    Correlation of changes from baseline in urinary protein/creatinine ratio with percent change from baseline in lipids and lipoprotein concentrations at Week 26.
15. Relationship Between Renal Effects and Lipid Changes: Urinary Protein/Creatinine Ratio and TG [ Time Frame: 52 Weeks ]
    Correlation of changes from baseline in urinary protein/creatinine ratio with percent change from baseline in lipids and lipoprotein concentrations at Week 52
16. Relationship Between Renal Effects and Lipid Changes: Urinary Protein/Creatinine Ratio and TC/HDL-C Ratio [ Time Frame: 26 weeks ]
    Correlation of changes from baseline in urinary protein/creatinine ratio with percent change from baseline in lipids and lipoprotein concentrations at Week 26.
17. Relationship Between Renal Effects and Lipid Changes: Urinary Protein/Creatinine Ratio and TC/HDL-C Ratio [ Time Frame: 52 Weeks ]
    Correlation of changes from baseline in urinary protein/creatinine ratio with percent change from baseline in lipids and lipoprotein concentrations at Week 52
18. Relationship Between Renal Effects and Lipid Changes: Urinary Protein/Creatinine Ratio and LDL-C/HDL-C Ratio [ Time Frame: 26 weeks ]
    Correlation of changes from baseline in urinary protein/creatinine ratio with percent change from baseline in lipids and lipoprotein concentrations at Week 26.
19. Relationship Between Renal Effects and Lipid Changes: Urinary Protein/Creatinine Ratio and LDL-C/HDL-C Ratio [ Time Frame: 52 Weeks ]
    Correlation of changes from baseline in urinary protein/creatinine ratio with percent change from baseline in lipids and lipoprotein concentrations at Week 52
20. Relationship Between Renal Effects and Lipid Changes: Urinary Protein/Creatinine Ratio and nonHDL-C/HDL-C Ratio [ Time Frame: 26 weeks ]
    Correlation of changes from baseline in urinary protein/creatinine ratio with percent change from baseline in lipids and lipoprotein concentrations at Week 26.
21. Relationship Between Renal Effects and Lipid Changes: Urinary Protein/Creatinine Ratio and nonHDL-C/HDL-C Ratio [ Time Frame: 52 Weeks ]
    Correlation of changes from baseline in urinary protein/creatinine ratio with percent change from baseline in lipids and lipoprotein concentrations at Week 52
22. Relationship Between Renal Effects and Lipid Changes: Urinary Protein/Creatinine Ratio and Apolipoprotein A-1 [ApoA-1] [ Time Frame: 26 weeks ]
    Correlation of changes from baseline in urinary protein/creatinine ratio with percent change from baseline in lipids and lipoprotein concentrations at Week 26.
23. Relationship Between Renal Effects and Lipid Changes: Urinary Protein/Creatinine Ratio and ApoA-1 [ Time Frame: 52 Weeks ]
    Correlation of changes from baseline in urinary protein/creatinine ratio with percent change from baseline in lipids and lipoprotein concentrations at Week 52
24. Relationship Between Renal Effects and Lipid Changes: Urinary Protein/Creatinine Ratio and Apolipoprotein B [ApoB] [ Time Frame: 26 weeks ]
    Correlation of changes from baseline in urinary protein/creatinine ratio with percent change from baseline in lipids and lipoprotein concentrations at Week 26.
25. Relationship Between Renal Effects and Lipid Changes: Urinary Protein/Creatinine Ratio and ApoB [ Time Frame: 52 Weeks ]
    Correlation of changes from baseline in urinary protein/creatinine ratio with percent change from baseline in lipids and lipoprotein concentrations at Week 52
26. Relationship Between Renal Effects and Lipid Changes: Urinary Protein/Creatinine Ratio and ApoB/ApoA-1 Ratio [ Time Frame: 26 weeks ]
    Correlation of changes from baseline in urinary protein/creatinine ratio with percent change from baseline in lipids and lipoprotein concentrations at Week 26.
27. Relationship Between Renal Effects and Lipid Changes: Urinary Protein/Creatinine Ratio and ApoB/ApoA-1 Ratio [ Time Frame: 52 Weeks ]
    Correlation of changes from baseline in urinary protein/creatinine ratio with percent change from baseline in lipids and lipoprotein concentrations at Week 52
28. Relationship Between Renal Effects and Lipid Changes: Urinary Albumin/Creatinine Ratio and TC [ Time Frame: 26 weeks ]
    Correlation of changes from baseline in urinary albumin/creatinine ratio with percent change from baseline in lipids and lipoprotein concentrations at Week 26.
29. Relationship Between Renal Effects and Lipid Changes: Urinary Albumin/Creatinine Ratio and TC [ Time Frame: 52 Weeks ]
    Correlation of changes from baseline in urinary albumin/creatinine ratio with percent change from baseline in lipids and lipoprotein concentrations at Week 52
30. Relationship Between Renal Effects and Lipid Changes: Urinary Albumin/Creatinine Ratio and LDL-C [ Time Frame: 26 weeks ]
    Correlation of changes from baseline in urinary albumin/creatinine ratio with percent change from baseline in lipids and lipoprotein concentrations at Week 26.
31. Relationship Between Renal Effects and Lipid Changes: Urinary Albumin/Creatinine Ratio and LDL-C [ Time Frame: 52 Weeks ]
    Correlation of changes from baseline in urinary albumin/creatinine ratio with percent change from baseline in lipids and lipoprotein concentrations at Week 52
32. Relationship Between Renal Effects and Lipid Changes: Urinary Albumin/Creatinine Ratio and HDL-C [ Time Frame: 26 weeks ]
    Correlation of changes from baseline in urinary albumin/creatinine ratio with percent change from baseline in lipids and lipoprotein concentrations at Week 26.
33. Relationship Between Renal Effects and Lipid Changes: Urinary Albumin/Creatinine Ratio and HDL-C [ Time Frame: 52 Weeks ]
    Correlation of changes from baseline in urinary albumin/creatinine ratio with percent change from baseline in lipids and lipoprotein concentrations at Week 52
34. Relationship Between Renal Effects and Lipid Changes: Urinary Albumin/Creatinine Ratio and nonHDL-C [ Time Frame: 26 weeks ]
    Correlation of changes from baseline in urinary albumin/creatinine ratio with percent change from baseline in lipids and lipoprotein concentrations at Week 26.
35. Relationship Between Renal Effects and Lipid Changes: Urinary Albumin/Creatinine Ratio and nonHDL-C [ Time Frame: 52 Weeks ]
    Correlation of changes from baseline in urinary albumin/creatinine ratio with percent change from baseline in lipids and lipoprotein concentrations at Week 52
36. Relationship Between Renal Effects and Lipid Changes: Urinary Albumin/Creatinine Ratio and TG [ Time Frame: 26 weeks ]
    Correlation of changes from baseline in urinary albumin/creatinine ratio with percent change from baseline in lipids and lipoprotein concentrations at Week 26.
37. Relationship Between Renal Effects and Lipid Changes: Urinary Albumin/Creatinine Ratio and TG [ Time Frame: 52 Weeks ]
    Correlation of changes from baseline in urinary albumin/creatinine ratio with percent change from baseline in lipids and lipoprotein concentrations at Week 52
38. Relationship Between Renal Effects and Lipid Changes: Urinary Albumin/Creatinine Ratio and TC/HDL-C Ratio [ Time Frame: 26 weeks ]
    Correlation of changes from baseline in urinary albumin/creatinine ratio with percent change from baseline in lipids and lipoprotein concentrations at Week 26.
39. Relationship Between Renal Effects and Lipid Changes: Urinary Albumin/Creatinine Ratio and TC/HDL-C Ratio [ Time Frame: 52 Weeks ]
    Correlation of changes from baseline in urinary albumin/creatinine ratio with percent change from baseline in lipids and lipoprotein concentrations at Week 52
40. Relationship Between Renal Effects and Lipid Changes: Urinary Albumin/Creatinine Ratio and LDL-C/HDL-C Ratio [ Time Frame: 26 weeks ]
    Correlation of changes from baseline in urinary albumin/creatinine ratio with percent change from baseline in lipids and lipoprotein concentrations at Week 26.
41. Relationship Between Renal Effects and Lipid Changes: Urinary Albumin/Creatinine Ratio and LDL-C/HDL-C Ratio [ Time Frame: 52 Weeks ]
    Correlation of changes from baseline in urinary albumin/creatinine ratio with percent change from baseline in lipids and lipoprotein concentrations at Week 52
42. Relationship Between Renal Effects and Lipid Changes: Urinary Albumin/Creatinine Ratio and nonHDL-C/HDL-C Ratio [ Time Frame: 26 weeks ]
    Correlation of changes from baseline in urinary albumin/creatinine ratio with percent change from baseline in lipids and lipoprotein concentrations at Week 26.
43. Relationship Between Renal Effects and Lipid Changes: Urinary Albumin/Creatinine Ratio and nonHDL-C/HDL-C Ratio [ Time Frame: 52 Weeks ]
    Correlation of changes from baseline in urinary albumin/creatinine ratio with percent change from baseline in lipids and lipoprotein concentrations at Week 52
44. Relationship Between Renal Effects and Lipid Changes: Urinary Albumin/Creatinine Ratio and ApoA-1 [ Time Frame: 26 weeks ]
    Correlation of changes from baseline in urinary albumin/creatinine ratio with percent change from baseline in lipids and lipoprotein concentrations at Week 26.
45. Relationship Between Renal Effects and Lipid Changes: Urinary Albumin/Creatinine Ratio and ApoA-1 [ Time Frame: 52 Weeks ]
    Correlation of changes from baseline in urinary albumin/creatinine ratio with percent change from baseline in lipids and lipoprotein concentrations at Week 52
46. Relationship Between Renal Effects and Lipid Changes: Urinary Albumin/Creatinine Ratio and ApoB [ Time Frame: 26 weeks ]
    Correlation of changes from baseline in urinary albumin/creatinine ratio with percent change from baseline in lipids and lipoprotein concentrations at Week 26.
47. Relationship Between Renal Effects and Lipid Changes: Urinary Albumin/Creatinine Ratio and ApoB [ Time Frame: 52 Weeks ]
    Correlation of changes from baseline in urinary albumin/creatinine ratio with percent change from baseline in lipids and lipoprotein concentrations at Week 52
48. Relationship Between Renal Effects and Lipid Changes: Urinary Albumin/Creatinine Ratio and ApoB/ApoA-1 Ratio [ Time Frame: 26 weeks ]
    Correlation of changes from baseline in urinary albumin/creatinine ratio with percent change from baseline in lipids and lipoprotein concentrations at Week 26.
49. Relationship Between Renal Effects and Lipid Changes: Urinary Albumin/Creatinine Ratio and ApoB/ApoA-1 Ratio [ Time Frame: 52 Weeks ]
    Correlation of changes from baseline in urinary albumin/creatinine ratio with percent change from baseline in lipids and lipoprotein concentrations at Week 52
50. Relationship Between Renal Effects and Lipid Changes: eGFR and TC [ Time Frame: 26 weeks ]
    Correlation of changes from baseline in eGFR with percent change from baseline in lipids and lipoprotein concentrations at Week 26.
51. Relationship Between Renal Effects and Lipid Changes: eGFR and TC [ Time Frame: 52 Weeks ]
    Correlation of changes from baseline in eGFR with percent change from baseline in lipids and lipoprotein concentrations at Week 52
52. Relationship Between Renal Effects and Lipid Changes: eGFR and LDL-C [ Time Frame: 26 weeks ]
    Correlation of changes from baseline in eGFR with percent change from baseline in lipids and lipoprotein concentrations at Week 26.
53. Relationship Between Renal Effects and Lipid Changes: eGFR and LDL-C [ Time Frame: 52 Weeks ]
    Correlation of changes from baseline in eGFR with percent change from baseline in lipids and lipoprotein concentrations at Week 52
54. Relationship Between Renal Effects and Lipid Changes: eGFR and HDL-C [ Time Frame: 26 weeks ]
    Correlation of changes from baseline in eGFR with percent change from baseline in lipids and lipoprotein concentrations at Week 26.
55. Relationship Between Renal Effects and Lipid Changes: eGFR and HDL-C [ Time Frame: 52 Weeks ]
    Correlation of changes from baseline in eGFR with percent change from baseline in lipids and lipoprotein concentrations at Week 52
56. Relationship Between Renal Effects and Lipid Changes: eGFR and nonHDL-C [ Time Frame: 26 weeks ]
    Correlation of changes from baseline in eGFR with percent change from baseline in lipids and lipoprotein concentrations at Week 26.
57. Relationship Between Renal Effects and Lipid Changes: eGFR and nonHDL-C [ Time Frame: 52 weeks ]
    Correlation of changes from baseline in eGFR with percent change from baseline in lipids and lipoprotein concentrations at Week 52
58. Relationship Between Renal Effects and Lipid Changes: eGFR and TG [ Time Frame: 26 weeks ]
    Correlation of changes from baseline in eGFR with percent change from baseline in lipids and lipoprotein concentrations at Week 26.
59. Relationship Between Renal Effects and Lipid Changes: eGFR and TG [ Time Frame: 52 weeks ]
    Correlation of changes from baseline in eGFR with percent change from baseline in lipids and lipoprotein concentrations at Week 52
60. Relationship Between Renal Effects and Lipid Changes: eGFR and TC/HDL-C Ratio [ Time Frame: 26 weeks ]
    Correlation of changes from baseline in eGFR with percent change from baseline in lipids and lipoprotein concentrations at Week 26.
61. Relationship Between Renal Effects and Lipid Changes: eGFR and TC/HDL-C Ratio [ Time Frame: 52 weeks ]
    Correlation of changes from baseline in eGFR with percent change from baseline in lipids and lipoprotein concentrations at Week 52
62. Relationship Between Renal Effects and Lipid Changes: eGFR and LDL-C/HDL-C Ratio [ Time Frame: 26 weeks ]
    Correlation of changes from baseline in eGFR with percent change from baseline in lipids and lipoprotein concentrations at Week 26.
63. Relationship Between Renal Effects and Lipid Changes: eGFR and LDL-C/HDL-C Ratio [ Time Frame: 52 weeks ]
    Correlation of changes from baseline in eGFR with percent change from baseline in lipids and lipoprotein concentrations at Week 52
64. Relationship Between Renal Effects and Lipid Changes: eGFR and nonHDL-C/HDL-C Ratio [ Time Frame: 26 weeks ]
    Correlation of changes from baseline in eGFR with percent change from baseline in lipids and lipoprotein concentrations at Week 26.
65. Relationship Between Renal Effects and Lipid Changes: eGFR and nonHDL-C/HDL-C Ratio [ Time Frame: 52 weeks ]
    Correlation of changes from baseline in eGFR with percent change from baseline in lipids and lipoprotein concentrations at Week 52
66. Relationship Between Renal Effects and Lipid Changes: eGFR and ApoA1 [ Time Frame: 26 weeks ]
    Correlation of changes from baseline in eGFR with percent change from baseline in lipids and lipoprotein concentrations at Week 26.
67. Relationship Between Renal Effects and Lipid Changes: eGFR and ApoA1 [ Time Frame: 52 weeks ]
    Correlation of changes from baseline in eGFR with percent change from baseline in lipids and lipoprotein concentrations at Week 52
68. Relationship Between Renal Effects and Lipid Changes: eGFR and ApoB [ Time Frame: 26 weeks ]
    Correlation of changes from baseline in eGFR with percent change from baseline in lipids and lipoprotein concentrations at Week 26.
69. Relationship Between Renal Effects and Lipid Changes: eGFR and ApoB [ Time Frame: 52 weeks ]
    Correlation of changes from baseline in eGFR with percent change from baseline in lipids and lipoprotein concentrations at Week 52
70. Relationship Between Renal Effects and Lipid Changes: eGFR and ApoB/ApoA-1 Ratio [ Time Frame: 26 weeks ]
    Correlation of changes from baseline in eGFR with percent change from baseline in lipids and lipoprotein concentrations at Week 26.
71. Relationship Between Renal Effects and Lipid Changes: eGFR and ApoB/ApoA-1 Ratio [ Time Frame: 52 weeks ]
    Correlation of changes from baseline in eGFR with percent change from baseline in lipids and lipoprotein concentrations at Week 52

Eligibility Criteria

• Ages Eligible for Study: 18 Years and older (Adult, Older Adult)
• Sexes Eligible for Study: All
• Accepts Healthy Volunteers: No

Criteria

Inclusion Criteria:

• hyperlipidemia
• urinary protein
• diabetes

Exclusion Criteria:

• previous rosuvastatin treatment < 6 months prior to Visit 1
• statin intolerance
• severe hypertension

Contacts and Locations

Locations

United States, Arizona

Research Site

Avondale, Arizona, United States

Research Site

Phoenix, Arizona, United States

United States, Arkansas

Research Site

Jonesboro, Arkansas, United States

United States, California

Research Site

Pasadena, California, United States

Research Site

Riverside, California, United States

Research Site

Santa Ana, California, United States

Research Site

West Hills, California, United States

United States, Florida

Research Site

Hollywood, Florida, United States

Research Site

Jacksonville, Florida, United States

Research Site

West Palm Beach, Florida, United States

United States, Georgia

Research Site

Augusta, Georgia, United States

United States, Kansas

Research Site

Topeka, Kansas, United States

United States, Massachusetts

Research Site

Springfield, Massachusetts, United States

United States, Michigan

Research Site

Detroit, Michigan, United States

United States, Missouri

Research Site

Columbia, Missouri, United States

Research Site

St. Louis, Missouri, United States

United States, New York

Research Site

Orchard Park, New York, United States

Research Site

Stony Brook, New York, United States

United States, North Carolina

Research Site

Winston Salem, North Carolina, United States

United States, Ohio

Research Site

Cincinnati, Ohio, United States

Research Site

Kettering, Ohio, United States

United States, Pennsylvania

Research Site

Pittsburg, Pennsylvania, United States

United States, South Carolina

Research Site

Columbia, South Carolina, United States

United States, Texas

Research Site

Dallas, Texas, United States

Research Site

Houston, Texas, United States

Research Site

Lubbock, Texas, United States

Research Site

San Antonio, Texas, United States

United States, Utah

Research Site

Ogden, Utah, United States

United States, Wisconsin

Research Site

Milwaukee, Wisconsin, United States

Argentina

Research Site

Buenos Aires, Argentina

Reasearch Site

La Plata, Argentina

Research Site

Moron, Argentina

Research Site

Quilmes, Argentina

Brazil

Research Site

Curitiba, Brazil

Research Site

Fortaleza, Brazil

Research Site

Goiania, Brazil

Research Site

Recife, Brazil

Research Site

Sao Paulo, Brazil

Bulgaria

Research Site

Burgas, Bulgaria

Research Site

Gabrovo, Bulgaria

Research Site

Pleven, Bulgaria

Research Site

Plovdiv, Bulgaria

Research Site

Sofia, Bulgaria

Research Site

Varna, Bulgaria

Research Site

Veliko Tarnovo, Bulgaria

Canada, British Columbia

Research Site

Vancouver, British Columbia, Canada

Canada, Ontario

Research Site

Courtice, Ontario, Canada

Research Site

North York, Ontario, Canada

Research Site

Oshawa, Ontario, Canada

Research Site

Ottawa, Ontario, Canada

Research Site

Richmond Hill, Ontario, Canada

Research Site

Scarborough, Ontario, Canada

Research Site

Thunder Bay, Ontario, Canada

Canada, Quebec

Research Site

Greenfield Park, Quebec, Canada

Research Site

Montreal, Quebec, Canada

Denmark

Research Site

Aalborg, Denmark

Research Site

Blegdamsvej 9, Denmark

Research Site

Farso, Denmark

Research Site

Gentofte, Denmark

Research Site

Hillerod, Denmark

Research Site

Hvidovre, Denmark

Research Site

Koge, Denmark

France

Research Site

Annonay, France

Research Site

Besançon, France

Research Site

Bondy, France

Research Site

Colmar, France

Research Site

Corbeil Essonnes, France

Research Site

Corsept, France

Research Site

Creil Cedex, France

Research Site

Grenoble Cedex, France

Research Site

La Chapelle Sur Erdre, France

Research Site

Nantes, France

Research Site

Paris, France

Research Site

Pessac, France

Research Site

Quimper, France

Hungary

Research Site

Baja, Hungary

Research Site

Balatonfured, Hungary

Research site

Budapest, Hungary

Research Site

Debrecen, Hungary

Research Site

Gyor, Hungary

Research site

Gyula, Hungary

Research Site

Hodmeztvasarhely, Hungary

Research Site

Kecskemét, Hungary

Research Site

Keszthely, Hungary

Research Site

Miskolc, Hungary

Research Site

Mosonmagyarovar, Hungary

Research Site

Nyiregyhaza, Hungary

Research Site

Szolnok, Hungary

Research Site

Székesfehérvár, Hungary

Research Site

Tatabanya, Hungary

Research Site

Zalaegerszeg, Hungary

Italy

Research Site

Acireale, CT, Italy

Research Site

Firenze, FI, Italy

Research Site

Roma, RM, Italy

Research Site

Sottomarnia Di Chioggia, VE, Italy

Research Site

Bergamo, Italy

Research Site

Cagliari, Italy

Research Site

Milano, Italy

Research Site

San Giovanni Rotondo, Italy

Research Site

Sassari, Italy

Research Site

Treviglio, Italy

Mexico

Research Site

Aguascalientes, Mexico

Research Site

Cauntla, Mexico

Research Site

Distrito Federal, Mexico

Research Site

Durango, Mexico

Research Site

Guadalajara, Mexico

Research Site

Saltillo, Mexico

Research Site

San Luis Potosi, Mexico

Research Site

Zapopan, Mexico

Romania

Research Site

Baia Mare, Romania

Research Site

Brasov, Romania

Research Site

Bucharest, Romania

Research Site

Craiova, Romania

Research Site

Lasi, Romania

Research Site

Targu Mures, Romania

Research Site

Timisoara, Romania

Sponsors and Collaborators

AstraZeneca

Investigators

• Study Director: AstraZeneca Crestor Medical Science Director, MD; AstraZeneca

More Information

Additional Information:

AstraZeneca Clinical Trial Information - Outside US 

Publications automatically indexed to this study by ClinicalTrials.gov Identifier (NCT Number):

de Zeeuw D, Anzalone DA, Cain VA, Cressman MD, Heerspink HJ, Molitoris BA, Monyak JT, Parving HH, Remuzzi G, Sowers JR, Vidt DG. Renal effects of atorvastatin and rosuvastatin in patients with diabetes who have progressive renal disease (PLANET I): a randomised clinical trial. Lancet Diabetes Endocrinol. 2015 Mar;3(3):181-90. doi: 10.1016/S2213-8587(14)70246-3. Epub 2015 Feb 4.

• Responsible Party: AstraZeneca
• ClinicalTrials.gov Identifier: NCT00296374
• Other Study ID Numbers: D3569C00007; PLANET 1
• First Posted: February 27, 2006
• Results First Posted: December 30, 2010
• Last Update Posted: September 1, 2011
• Last Verified: August 2011

Keywords provided by AstraZeneca:

Hyperlipidemia; Proteinuria; Diabetes Mellitus

Additional relevant MeSH terms:

Proteinuria; Diabetes Mellitus; Glucose Metabolism Disorders; Metabolic Diseases; Endocrine System Diseases; Urination Disorders; Urologic Diseases; Urological Manifestations; Atorvastatin; Rosuvastatin Calcium; Anticholesteremic Agents; Hypolipidemic Agents; Antimetabolites; Molecular Mechanisms of Pharmacological Action; Lipid Regulating Agents; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Enzyme Inhibitors